Table 2.
Treatments and outcome
| Treatments | Oxygen and ventilation support, n (%) | |
| - Nasal oxygen therapy | 23 (13,9%) | |
| - High concentration oxygen therapy | 67 (42,4%) | |
| - High flow nasal oxygen therapy | 99 (60,0%) | |
| - Noninvasive ventilation | 45 (27,2%) | |
| - Mechanical ventilation | 95 (57,6%) | |
| Corticosteroids, n (%) | ||
| Dexamethasone 6mg/d | 165 (100%) | |
| Anticoagulation, n (%) | ||
| - Enoxaparine | 165 (100%) | |
| Anti-platelet aggregation therapy, n (%) | ||
| - Acetylsalicylic acid | 165 (100%) | |
| Adjuvant therapies: | ||
| Vitamin C 2000mg/d | 165 (100%) | |
| Vitamin D 25000UI/week | 165 (100%) | |
| Zinc 45mg/d | 165 (100%) | |
| Proton pomp inhibitor 40mg/d | 165 (100%) | |
| Therapeutic plasma exchange, n (%) | 57 (34,5%) | |
| Vascular access: | ||
| - Jugular | 19 (33,3%) | |
| - Femoral | 38 (66,7%) | |
| Substitution fluid: | ||
| - Fresh Frozen Plasma | 100% | |
| Exchange volume (mL), mean ± SD | 2915 ± 338 | |
| Circuit anticoagulation: | ||
| - Non-Fractioned Heparin | 100% | |
| Number of sessions, n | 5 | |
| Session length of time (min), mean ± SD | 119 ± 24 | |
| Outcome | Length of stay (days), median [IQR] | 15 [11 – 24] |
| Extubation rate, n (%) | 10 (10,5%) | |
| Survival rate, n (%) | 80 (48,5%) | |
| Mortality rate, n (%) | 85 (51,5%) |